# Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

> **NCT02814643** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 103 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Benralizumab
- **DRUG:** Benralizumab Placebo
- **DRUG:** Seasonal influenza virus vaccine

## Key facts

- **NCT ID:** NCT02814643
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-01
- **Primary completion:** 2017-01-24
- **Final completion:** 2017-01-24
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2018-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02814643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02814643, "Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02814643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*